

**SINGAPORE
BIOTECH INVEST**

21-22 March 2017

Singapore Exchange (SGX)

**HONG KONG
BIOTECH INVEST**

23-24 March 2017

KPMG Hong Kong

**AUSTRALIA-CHINA
BIOTECH INVEST**

27-28 March 2017

Shanghai Marriott Hotel City Centre

Dr Geoffrey Dow, Founder & CEO, 60 Degrees Pharmaceuticals

Dr. Geoffrey S. Dow is the Founder and CEO of 60 Degrees Pharmaceuticals, LLC “60P”, a pharmaceutical company founded in Washington, DC in 2010. Currently, he is managing the Company’s efforts to commercialize a malaria prophylactic drug (tafenoquine) and conduct Phase I/II clinical programs to evaluate the potential utility of several host targeted molecules as antiviral therapeutics (celgosivir and modipafant). Dr. Dow received both his undergraduate (Biotechnology, 1993) and doctoral (Parasitology, 2000) degrees at Murdoch University in Perth, Australia. Additionally, he earned his MBA at the University of Maryland in College Park, MD in the United States (2012). Dr. Dow worked at Walter Reed Army Institute of Research (WRAIR), Division of Experimental Therapeutics in Washington, DC from 2000 – 2012. During his time there he was the Project Leader on both Pf Histone Deacetylase Inhibitors (2006-2008) and Next Generation Quinoline Methanols (2003-2011). He also was a Clinical Research Scientist/Assistant Project Manager for the GSK-Army Tafenoquine Development Team (2004-2008). Later Dr. Dow continued to work on the tafenoquine molecule at the United States Army Medical Materiel Development Activity, Division of Pharmaceutical Substances (2011-2013). There he served as Senior Technical Advisor, IND38503: Tafenoquine and Leader, Regulatory Strategy and Clinical Trial Management for IND38503: Tafenoquine. Beyond being able to raise private funds for 60P, Dr. Dow has successfully written and been awarded several grants to support the Company’s research. Most notable from the Singapore Ministry of Health approximately \$4,000,000 SGD to evaluate efficacy and safety of celgosivir and modipafant in dengue patients. Finally, Dr. Dow has contributed to a number of published articles in the field of malaria and has submitted 8 patent series as a sole or co-inventor in the areas of antiviral and antimalarial drug development.

